title: Bicistronic lentiviruses containing a viral 2A cleavage sequence reliably co-express two proteins and restore vision to an animal model of LCA1.
abstract: The disease processes underlying inherited retinal disease are complex and are not completely understood. Many of the corrective gene therapies designed to treat diseases linked to mutations in genes specifically expressed in photoreceptor cells restore function to these cells but fail to stop progression of the disease. There is growing consensus that effective treatments for these diseases will require delivery of multiple therapeutic proteins that will be selected to treat specific aspects of the disease process. The purpose of this study was to design a lentiviral transgene that reliably expresses all of the proteins it encodes and does so in a consistent manner among infected cells. We show, using both in vitro and in vivo analyses, that bicistronic lentiviral transgenes encoding two fluorescent proteins fused to a viral 2A-like cleavage peptide meet these expression criteria. To determine if this transgene design is suitable for therapeutic applications, we replaced one of the fluorescent protein genes with the gene encoding guanylate cyclase-1 (GC1) and delivered lentivirus carrying this transgene to the retinas of the GUCY1*B avian model of Leber congenital amaurosis-1 (LCA1). GUCY1*B chickens carry a null mutation in the GC1 gene that disrupts photoreceptor function and causes blindness at hatching, a phenotype that closely matches that observed in humans with LCA1. We found that treatment of these animals with the 2A lentivector encoding GC1 restored vision to these animals as evidenced by the presence of optokinetic reflexes. We conclude that 2A-like peptides, with proper optimization, can be successfully incorporated into therapeutic vectors designed to deliver multiple proteins to neural retinal. These results highlight the potential of this vector design to serve as a platform for the development of combination therapies designed to enhance or prolong the benefits of corrective gene therapies.
authors.affiliation: Department of Neuroscience, University of Florida McKnight Brain Institute, Gainesville, Florida, United States of America.
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Verrier
authors.forename: Irina
authors.initials: I
authors.lastname: Madorsky
authors.forename: William E
authors.initials: WE
authors.lastname: Coggin
authors.forename: Mero
authors.initials: M
authors.lastname: Geesey
authors.forename: Michael
authors.initials: M
authors.lastname: Hochman
authors.forename: Elleanor
authors.initials: E
authors.lastname: Walling
authors.forename: Daniel
authors.initials: D
authors.lastname: Daroszewski
authors.forename: Kristofer S
authors.initials: KS
authors.lastname: Eccles
authors.forename: Rachel
authors.initials: R
authors.lastname: Ludlow
authors.forename: Susan L
authors.initials: SL
authors.lastname: Semple-Rowland
mesh_terms: D000818:Animals; D002642:Chick Embryo; D004195:Disease Models, Animal; D015870:Gene Expression; D005814:Genes, Viral / Q000235:genetics*; D005822:Genetic Vectors / Q000235:genetics*; D006162:Guanylate Cyclase / Q000235:genetics; D057809:HEK293 Cells; D006801:Humans; D057130:Leber Congenital Amaurosis / Q000235:genetics / Q000503:physiopathology* / Q000628:therapy; D016086:Lentivirus / Q000235:genetics*; D008164:Luminescent Proteins / Q000235:genetics*; D011401:Promoter Regions, Genetic / Q000235:genetics; D011956:Receptors, Cell Surface / Q000235:genetics; D020127:Recovery of Function / Q000235:genetics*; D012160:Retina / Q000378:metabolism / Q000503:physiopathology; D014162:Transfection; D019076:Transgenes / Q000235:genetics; D014785:Vision, Ocular / Q000502:physiology*
chemical_list: D008164:Luminescent Proteins; D011956:Receptors, Cell Surface; C110715:guanylate cyclase 1; D006162:Guanylate Cyclase